-transparent.png){kind=logo}
Pulmonary nocardiosis during immunosuppressive therapy for idiopathic pulmonary fibrosis. 2000
Y Maeno, and
Y Sando, and
M Ubukata, and
T Maeno, and
S Tajima, and
T Hosono, and
M Sato, and
M Tsukagoshi, and
T Suga, and
M Kurabayashi, and
R Nagai
Second Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.
Nocardiosis is a subacute or chronic suppurative infection caused by Nocardia species. Although it is more common in immunocompromised hosts, idiopathic pulmonary fibrosis (IPF) has not been recognized as a predisposing factor for nocardial infection. We report a case of IPF, in which pulmonary nocardiosis developed during treatment with prednisolone and cyclophosphamide. The risk of pulmonary nocardiosis may be increased in cases of IPF on immunosuppressive therapy. Since IPF often accompanies lung carcinoma, it is important to correctly differentiate nocardiosis from carcinoma.
Related Publications
Y Maeno, and
Y Sando, and
M Ubukata, and
T Maeno, and
S Tajima, and
T Hosono, and
M Sato, and
M Tsukagoshi, and
T Suga, and
M Kurabayashi, and
R Nagai
November 1994,
The European respiratory journal,
Y Maeno, and
Y Sando, and
M Ubukata, and
T Maeno, and
S Tajima, and
T Hosono, and
M Sato, and
M Tsukagoshi, and
T Suga, and
M Kurabayashi, and
R Nagai
January 2004,
The Pediatric infectious disease journal,
Y Maeno, and
Y Sando, and
M Ubukata, and
T Maeno, and
S Tajima, and
T Hosono, and
M Sato, and
M Tsukagoshi, and
T Suga, and
M Kurabayashi, and
R Nagai
June 2005,
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Y Maeno, and
Y Sando, and
M Ubukata, and
T Maeno, and
S Tajima, and
T Hosono, and
M Sato, and
M Tsukagoshi, and
T Suga, and
M Kurabayashi, and
R Nagai
May 2016,
Journal of medical case reports,
Y Maeno, and
Y Sando, and
M Ubukata, and
T Maeno, and
S Tajima, and
T Hosono, and
M Sato, and
M Tsukagoshi, and
T Suga, and
M Kurabayashi, and
R Nagai
January 2005,
Revista portuguesa de pneumologia,
Y Maeno, and
Y Sando, and
M Ubukata, and
T Maeno, and
S Tajima, and
T Hosono, and
M Sato, and
M Tsukagoshi, and
T Suga, and
M Kurabayashi, and
R Nagai
November 2005,
The New England journal of medicine,
Y Maeno, and
Y Sando, and
M Ubukata, and
T Maeno, and
S Tajima, and
T Hosono, and
M Sato, and
M Tsukagoshi, and
T Suga, and
M Kurabayashi, and
R Nagai
September 2001,
Current opinion in pulmonary medicine,
Y Maeno, and
Y Sando, and
M Ubukata, and
T Maeno, and
S Tajima, and
T Hosono, and
M Sato, and
M Tsukagoshi, and
T Suga, and
M Kurabayashi, and
R Nagai
September 2005,
Chest,
Y Maeno, and
Y Sando, and
M Ubukata, and
T Maeno, and
S Tajima, and
T Hosono, and
M Sato, and
M Tsukagoshi, and
T Suga, and
M Kurabayashi, and
R Nagai
August 2019,
American journal of respiratory and critical care medicine,
Y Maeno, and
Y Sando, and
M Ubukata, and
T Maeno, and
S Tajima, and
T Hosono, and
M Sato, and
M Tsukagoshi, and
T Suga, and
M Kurabayashi, and
R Nagai
July 2008,
Expert opinion on investigational drugs,
